Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MDD

- PMLiVE

Healthware Group report on depression care in Italy highlights need for digital therapeutics

Mental health disorders are the fifth leading cause of disability adjusted life years in Italy

- PMLiVE

Mental Health Awareness Week

This year the theme of Mental Health Awareness Week is loneliness, focusing on the impact of it on our mental health and the practical steps we can take to address...

Mednet Group

Supporting Mental Health During a Global Pandemic

Sam Duboc, Chair & CEO of MindBeacon, explores virtual care and telehealth for treating depression, anxiety, addiction, and other conditions; mental health issues brought on by COVID-19; and how to...

Impetus Digital

- PMLiVE

Acadia’s Nuplazid misses the mark in major depressive disorder trial

Company's efforts to extend drug's reach fall flat

Impetus Digital Fireside Chat with with Jon Sockell, Co-Founder/COO of Limbix

Jon Sockell, Co-founder and COO of Limbix, sits down with us in this Fireside Chat. See how Limbix is paving the way for prescription digital therapeutics and learn from their trials,...

Impetus Digital

- PMLiVE

FDA approves Allergan’s biodegradable glaucoma implant drug

Reduces intraocular pressure in glaucoma or ocular hypertension

- PMLiVE

Allergan and Editas claim a CRISPR first in inherited blindness study

Partners are first to use CRISPR to edit cells inside the body

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

AbbVie says Allergan takeover delayed by FTC verdict

Merger now likely to complete in second quarter rather than first

- PMLiVE

AbbVie/Allergan merger faces renewed public opposition despite divestments

Consumer groups and public interest organisations raise new concerns

- PMLiVE

Botox strength bolsters Allergan ahead of AbbVie takeover

Speciality drugmaker posted a 6.6% sales increase in the last quarter

- PMLiVE

NICE knocks back J&J’s depression nasal spray Spravato

Cites clinical and pricing uncertainty as basis of rejection

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links